Accuracy of post-radiotherapy biopsy before salvage radical prostatectomy

Size: px
Start display at page:

Download "Accuracy of post-radiotherapy biopsy before salvage radical prostatectomy"

Transcription

1 Accuracy of post-radiotherapy biopsy before salvage radical prostatectomy Joshua J. Meeks, Marc Walker*, Melanie Bernstein, Matthew Kent and James A. Eastham Urology Service, Department of Surgery and Department of Biostatistics and Epidemiology, Memorial Sloan-Kettering Cancer Center, New York, NY, and *Department of Surgery, Urology Service, Tripler Army Medical Center, Honolulu, HI, USA Supported by the Sidney Kimmel Center for Prostate and Urologic Cancers. Objective To determine whether post-radiotherapy (RT) biopsy (PRB) adequately predicts the presence, location, and histological features of cancer in the salvage radical prostatectomy (SRP) specimen. Before salvage treatment, a PRB is required to confirm the presence of locally recurrent or persistent cancer and to determine the extent and location of the prostate cancer. Patients and Methods SRP was performed between 1998 and 2011 on 198 patients. All patients underwent a PRB. PRB and SRP specimens were evaluated by a genitourinary pathologist. Patients had external-beam RT alone (EBRT; 71%) or brachytherapy with or without EBRT (29%). Results Of the men undergoing SRP, 26 (14%) were clinical stage T3, with 13% of PRBs with Gleason score 8. Cancer was unilateral in 120 (61%) biopsies, with contralateral or bilateral prostate cancer at SRP in 49%. In the SRP specimen, cancer was multifocal in 57%. Cancer was upgraded at SRP in 58% of men, with 20% having an increase in primary Gleason grade. The accuracy of PRB varied by region from 62% to 76%, with undetected cancers ranging from 12% to 26% and most likely to occur at the mid-gland. Conclusions Radiation-recurrent prostate cancers were often multifocal, and biopsy missed up to 20% of tumours. More than half of the cancers were upgraded at SRP, and many that were unilateral on PRB were bilateral at SRP. Keywords prostate biopsy, prostate cancer, radiation therapy, radical prostatectomy Introduction More than men in the USA will be diagnosed with prostate cancer in 2012 [1], and half of these men will choose radiotherapy (RT) for their treatment [2]. Depending on risk status, 20 40% of men treated with RT for clinically localised prostate cancer will have biochemical recurrence (BCR) 10 years after treatment [3]. Without intervention after BCR, the rate of clinically detectable recurrence at 5 years is 75%, with half of these patients having distant metastasis [4]. Yet, >70% of recurrences that occur early after RT are due to persistent or radiation-resistant local disease [5]. Thus, timely salvage intervention after RT may be offered to patients with >10 years life expectancy, localised recurrence, and prostate cancer detected at post-rt biopsy (PRB). The ability of the PRB to accurately characterise the extent and location of residual cancer is critical to treatment planning. If the PRB identifies a small focus of prostate cancer on one side of the prostate, some men will consider focal ablative techniques, whereas young patients with multifocal or high-grade disease may be best treated with whole-gland ablation or salvage radical prostatectomy (SRP) [6]. To date, no study has determined the accuracy of the PRB to predict histological findings in the SRP specimen. Patients and Methods A prospectively accumulated database of men who developed BCR after RT for presumed clinically localised BJU International 112, doi: /bju.12015

2 Accuracy of post-radiotherapy biopsy before salvage RP prostate cancer and sought surgical therapy at Memorial Sloan-Kettering Cancer Center was collected with Institutional Review Board approval. All men had a PRB with review of the biopsy and SRP specimen by a genitourinary pathologist. Our cohort (220 patients) consisted of patients who had had SRP after receiving RT. Patients who underwent SRP before 1997, who did not have PRB and consistent pathological evaluation of SRP specimens, were excluded (22 patients), leaving a final cohort of 198 patients. Most patients underwent biopsy at our institution and all patients had a prostate biopsy with 12 cores with assistance from a radiological technologist for consistency. To determine the accuracy of the PRB, we compared the anatomical location and grade of the PRB with the corresponding regions of the prostate at SRP. These anatomical regions (apex, mid, and base) of both the right and left sides were compared with the corresponding regions of the SRP specimen. In all, 121 patients had detailed anatomical biopsies of the apex, mid, and base of the gland and were the primary cohort for the study. For the remaining 77, only laterality was recorded. In many cases, SRP specimens were sectioned en bloc (Fig. 1). Accuracy was defined as a positive or negative PRB result in a given region of the prostate confirmed in the SRP specimen. The primary and secondary Gleason grade of the PRB was compared with final primary and secondary Gleason grade of the SRP specimen. In addition, tumour multifocality was recorded in the SRP specimen. Fig. 1 Tumour map of SRP specimen. Prostates are sectioned en bloc from apex (A) to base (G). Black lines indicate high-grade prostate cancer, Gleason score 7; blue lines indicate extraprostatic extension; green lines indicate Gleason score of 6. BN, bladder neck margin; L, left; LA, left apical margin; LN, lymph node; LSV, left seminal vesicle; R, right; RA, right apical margin; RSV, right seminal vesicle. Each bar of scale represents 1 mm, total of 25 mm. A R F L B C D E G BN RA LA RSV LSV LN 1 Results The characteristics of the 198 men who underwent PRB and SRP are listed in Table 1. The median (interquartile range) PSA level was 3.7 (1.7, 6.5) ng/ml. The most common form of RT was external-beam RT (EBRT; 132/187 patients; 71%), with 55 patients (55/187; 29%) undergoing brachytherapy or both EBRT and brachytherapy. The most common clinical stage was T2 (89/186; 48%), whereas it was T3a in 26 (26/186; 14%). Almost half of PRBs identified Gleason score 7 cancer (92/192; 48%), with 24 (24/192; 13%) Gleason score 8. Most SRPs were performed open (175/198; 88%). Surgical margins were positive in 14% (27/198), despite advanced pathological stage in 56% (109/195) of SRP specimens ( pt3), including 26% (51/195) pt3b and 6% (12/195) pt4. Gleason score 8 was present in 35% (58/164) of SRP specimens. Table 2 describes the anatomical location of the positive PRBs. Overall, positive PRBs ranged from 38% at the right base to 46% of the right apex. Each SRP specimen was evaluated for the location and grade of prostate cancer (Fig. 1; Table 3). Most (110/193 [57%]) of the cancers were multifocal. In multifocal cancers, the most common cancer location was the right Table 1 Patient characteristics (N = 198). Characteristic N (%) Clinical stage (n = 186): T1 71 (38) T2 89 (48) T3a 15 (8) T3b 11 (6) Clinical Gleason score (n = 192): 6 76 (40) 7 92 (48) 8 24 (13) Pathological stage (n = 195): pt0 2 (1) pt2 84 (43) pt3a 45 (23) pt3b 51 (26) pt3c 1 (1) pt4 12 (6) Pathological Gleason score (n = 164): Unable to grade 34 (17) 6 5 (3) (62) 8 58 (35) Type of RT (n = 187): Brachytherapy 55 (29) EBRT 132 (71) Type of SRP: Open 175 (88) Laparoscopic 15 (8) Robot-assisted 8 (4) Positive surgical margins 27 (14) Seminal vesicle invasion 61 (31) Multifocal prostate cancer (n = 193) 110 (57) 2013 BJU International 309

3 Meeks et al. mid-gland (55/88 [63%]) and right apex (53/88 [60%]), whereas non-multifocal tumours were most commonly located in the right apex (28/61 [46%]). The base was the least likely prostate cancer location. Comparison of PRB with SRP Pathology Based on final pathology, prostate cancers were categorised as multifocal (92) or unifocal (55). Tumours that were multifocal had higher frequency of positive PRBs among all regions of the prostate. In patients with multifocal disease, the left mid-gland was the most common source of positive PRBs (46/92 [50%]), whereas the right apex was the most common location of positive PRBs in unifocal tumours (23/55 [42%]). Table 4 shows the agreement rates between PRB and SRP results. Agreement rates ranged from 62% to 76% between different regions of the prostate. Undetected cancer rates from PRBs ranged from 12% to 26%, with the right mid-gland having the greatest frequency of missed cancers (Table 5). The positive predictive value of PRB was 69% with a negative predictive value of 70%. There was a high rate of upgraded tumour grades from PRB to SRP specimen, with 58% (92/158) of patients upgraded from PRB, including 20% primary Gleason grade (31/158), 20% (32/158) secondary Gleason grade, and 18% (29/158) where both the primary and the secondary Gleason grades were increased. Only 3% (4/158) of PRBs were downgraded (4/158). In patients with unilaterally localised positive biopsies, final pathology was unilateral in only half (Table 6). Table 2 Positive PRB results. Biopsy location All Patients (N = 151), Table 3 Positive SRP pathological results. Pathological location All patients (N = 150), Unifocal (n = 61), Multifocal (n = 88), Right apex 69 (46) Right mid-gland 64 (42) Right base 57 (38) Left apex 62 (41) Left mid-gland 64 (42) Left base 62 (41) Right apex 82 (55) 28 (46) 53 (60) Right mid-gland 79 (53) 23 (38) 55 (63) Right base 49 (33) 10 (16) 38 (43) Left apex 69 (46) 21 (34) 47 (53) Left mid-gland 73 (49) 22 (36) 50 (57) Left base 49 (33) 15 (25) 33 (38) Table 4 PRB results compared with SRP with agreement rates. Location PRB SRP, n Agreement + - Overall (n = 121), Multifocal (n = 75), Unifocal (n = 45), Right: apex (76) 54 (72) 37 (82) mid-gland (62) 45 (60) 30 (67) base (74) 57 (76) 32 (71) Left: apex (66) 47 (63) 32 (71) mid-gland (68) 55 (73) 30 (67) base (65) 46 (61) 32 (71) Table 5 Locations of undetected prostate cancers by PRB (negative prostate biopsy results with cancer present at SRP). Location Right, Left, Apex 22 (18) 24 (20) Mid-gland 31 (27) 21 (17) Base 14 (12) 14 (12) BJU International

4 Accuracy of post-radiotherapy biopsy before salvage RP Table 6 Results of unilateral positive PRB. Discussion Right unilateral positive (n = 64), Left unilateral positive (n = 56), Ipsilateral positive 35 (55) 26 (46) Contralateral positive 1 (1) 4 (7) Bilateral positive 28 (44) 26 (46) The goal of the present study was to describe the accuracy of PRB to identify prostate cancer in a given location of the prostate before SRP. In a study comparing 250 non-irradiated RP specimens with prostate biopsies, the greatest accuracy was at the base (64%), followed by the mid-gland (53%), with the apex having the lowest accuracy (43%) [2]. We showed greater rates of accuracy for all regions of the prostate than previously reported for non-irradiated prostates. This may be because of the higher frequency of high-grade multifocal disease in patients after RT, or perhaps as a result of better sampling of the typically small post-radiation gland. In another study comparing 281 prostate biopsies with RP specimens, the only predictor that increased the accuracy of the prostate biopsy was the absence of multifocality [7]. In that study, multifocal tumours were present in 77% of patients, whereas tumours were multifocal in only 57% in the present study. The accuracy of PRB in the present study was slightly greater in four of six anatomical regions from tumours that were non-multifocal compared with multifocal tumours. The cohort described in the present series is the largest single-institution series of SRPs. Pathological analysis of these previously irradiated prostates may further our knowledge of potentially radiation-resistant regions of the prostate. In this cohort, the most common area to harbour prostate cancer was the right apex in which more than half of prostates (55%) had persistent prostate cancer. This suggests that the apex may be particularly difficult to target with RT either because of shielding by the pelvis or because it receives less radiation to prevent damage to the rhabdosphincter. The least common location for tumours was the base (33% for both sides). A prior study of 47 SRPs similarly found the base to be the least common location of radiation recurrent prostate cancer [8]. In patients who have had prior RT, the role of PRB remains controversial. Currently, the American Society for Therapeutic Radiology and Oncology does not recommend routine PRB, but rather recommends following PSA levels as a marker for recurrent disease [9]. In an unbiased cohort (in regard to PSA), the rate of positive PRB was at 50% at 13 months but decreased to 30% at 30 months [10]. The management of patients with a positive biopsy result but normal PSA levels/kinetics remains controversial. The average time from RT to treatment of prostate cancer relapse is 5 years if BCR is dependent on the use of PSA by the American Society for Therapeutic Radiology and Oncology criteria [11]. Thus, those selecting SRP may benefit from earlier intervention to reduce the rates of advanced disease [12]. The rate of upgrading at SRP was high at 58%, with 20% increasing at least one primary Gleason grade compared with the non-irradiated prostate, with a reported range of 25% to 57% [13,14]. All samples, both PRBs and SRPs, were reviewed by a dedicated genitourinary pathologist at a high-volume institution. Previous investigations of upgrading suggest that the highest rate of upgrading occurs when the biopsy and prostatectomy are performed at separate institutions and, therefore, graded by different pathologists [15]. An important variable that is poorly understood is the effect of RT on the Gleason grading system of prostate biopsy. As the largest series of SRP specimens, the high rate of upgrading confirms the difficulty in making a Gleason grade on PRBs compared with final RP specimens. Two factors may have affected the rate of upgrading. First, there was a high rate of Gleason score 8 (35%) at SRP. Second, almost 80% of prostates had residual radiation treatment effects. The rate of downgrading from prostate biopsy to prostatectomy is often lower than the rate of upgrading, but maybehighlyvariablewitharangebetween5%and25% [15]. In the present study, only 3% of biopsies were downgraded at SRP, suggesting a far greater likelihood that larger sampling of the tumour would show high-grade disease. This may also be explained by the difficulty in discerning low-grade tumours from normal prostate glands with altered architecture from RT. The management of patients with recurrent prostate cancer after RT remains a difficult situation. Because most recurrences are local, salvage treatment directed at the prostate gland should be considered by the patient and physician because uncontrolled local disease has a high rate of metastatic spread [16]. One possibility for salvage therapy could be focal therapy directed at biopsy-predicted focal regions of the prostate. In the present series, unilateral biopsy predicted the location of the tumour in about half of cases. Thus, half-gland-directed therapy would result in missed tumours half of the time. For younger patients, the advantage of whole-gland removal by SRP remains a viable option of staging and cancer control [6]. Several limitations of the present study deserve mention. First, the location of the tumours was categorised by trained genitourinary pathologist, but interobserver variation in categorising the tumour location may vary by pathologist. Second, the grade of pathology may also be subject to interpreter variability. The PRBs recorded are 2013 BJU International 311

5 Meeks et al. standard 12 core template biopsies and more thorough mapping-guided biopsies, potentially through perineal approach, with or without MRI assistance may detect higher rates of cancer. Finally, the patients who were able to undergo SRP bias the study because they may have less aggressive disease. Men with more advanced disease may not be candidates for surgery and could alter the accuracy of PRB. In conclusion, the accuracy of PRBs ranges from 62% to 74%, with the rate of previously undetected tumours ranging from 12% to 26% at SRP. Multifocal tumours occur in more than half of patients, and unilateral biopsy results are inaccurate in half of prostates after RT. Almost 60% of tumours are upgraded at SRP. Although PRB is useful for detection of recurrent prostate cancer after RT, far more accurate information is obtained at SRP. Thus, patients who elect salvage focal therapy may have higher rates of disease recurrence compared with those who choose whole-gland treatment or removal. Conflict of Interest None declared. References 1 Siegel R, Naishadham D, Jemal A. Cancer statistics, CA Cancer J Clin 2012; 62: Abdollah F, Sun M, Thuret R et al. A competing-risks analysis of survival after alternative treatment modalities for prostate cancer patients: Eur Urol 2011; 59: Alicikus ZA, Yamada Y, Zhang Z et al. Ten-year outcomes of high-dose, intensity-modulated radiotherapy for localized prostate cancer. Cancer 2011; 117: Lee WR, Hanks GE, Hanlon A. Increasing prostate-specific antigen profile following definitive radiation therapy for localized prostate cancer: clinical observations. J Clin Oncol 1997; 15: Zagars GK, Pollack A, von Eschenbach AC. Prostate cancer and radiation therapy the message conveyed by serum prostate-specific antigen. Int J Radiat Oncol Biol Phys 1995; 33: Pisters LL, Leibovici D, Blute M et al. Locally recurrent prostate cancer after initial radiation therapy: a comparison of salvage radical prostatectomy versus cryotherapy. J Urol 2009; 182: Schulte RT, Wood DP, Daignault S, Shah RB, Wei JT. Utility of extended pattern prostate biopsies for tumor localization: pathologic correlations after radical prostatectomy. Cancer 2008; 113: Huang WC, Kuroiwa K, Serio AM et al. The anatomical and pathological characteristics of irradiated prostate cancers may influence the oncological efficacy of salvage ablative therapies. J Urol 2007; 177: Cox JD, Gallagher MJ, Hammond EH, Kaplan RS, Schellhammer PF. Consensus statements on radiation therapy of prostate cancer: guidelines for prostate re-biopsy after radiation and for radiation therapy with rising prostate-specific antigen levels after radical prostatectomy. American Society for Therapeutic Radiology and Oncology Consensus Panel. J Clin Oncol 1999; 17: Crook JM, Perry GA, Robertson S, Esche BA. Routine prostate biopsies following radiotherapy for prostate cancer: results for 226 patients. Urology 1995; 45: Stephenson AJ. Role of salvage radical prostatectomy for recurrent prostate cancer after radiation therapy. J Clin Oncol 2005; 23: Chade DC, Shariat SF, Cronin AM et al. Salvage radical prostatectomy for radiation-recurrent prostate cancer: a multi-institutional collaboration. Eur Urol 2011; 60: Carlson GD, Calvanese CB, Kahane H, Epstein JI. Accuracy of biopsy gleason scores from a large uropathology laboratory: use of a diagnostic protocol to minimize observer variability. Urology 1998; 51: Lattouf J-B, Saad F. Gleason score on biopsy: is it reliable for predicting the final grade on pathology? BJU Int 2002; 90: Steinberg DM, Sauvageot J, Piantadosi S, Epstein JI. Correlation of prostate needle biopsy and radical prostatectomy Gleason grade in academic and community settings. Am J Surg Pathol 1997; 21: Fuks Z, Leibel SA, Wallner KE et al. The effect of local control on metastatic dissemination in carcinoma of the prostate: long-term results in patients treated with 125I implantation. Int J Radiat Oncol Biol Phys 1991; 21: Correspondence: James A. Eastham, Urology Service, Department of Surgery, Memorial Sloan-Kettering Cancer Center, 353 East 68th Street, New York, NY 10021, USA. easthamj@mkscc.org Abbreviations: BCR, biochemical recurrence; (EB)RT, (external beam) radiotherapy; (S)RP, (salvage) radical prostatectomy BJU International

Outcomes Following Negative Prostate Biopsy for Patients with Persistent Disease after Radiotherapy for Prostate Cancer

Outcomes Following Negative Prostate Biopsy for Patients with Persistent Disease after Radiotherapy for Prostate Cancer Clinical Urology Post-radiotherapy Prostate Biopsy for Recurrent Disease International Braz J Urol Vol. 36 (1): 44-48, January - February, 2010 doi: 10.1590/S1677-55382010000100007 Outcomes Following Negative

More information

Case Discussions: Prostate Cancer

Case Discussions: Prostate Cancer Case Discussions: Prostate Cancer Andrew J. Stephenson, MD FRCSC FACS Chief, Urologic Oncology Glickman Urological and Kidney Institute Cleveland Clinic Elevated PSA 1 54 yo, healthy male, family Hx of

More information

Salvage prostatectomy for post-radiation adenocarcinoma with treatment effect: Pathological and oncological outcomes

Salvage prostatectomy for post-radiation adenocarcinoma with treatment effect: Pathological and oncological outcomes ORIGINAL RESEARCH Salvage prostatectomy for post-radiation adenocarcinoma with treatment effect: Pathological and oncological outcomes Michael J. Metcalfe, MD ; Patricia Troncoso, MD 2 ; Charles C. Guo,

More information

Disease-specific death and metastasis do not occur in patients with Gleason score 6 at radical prostatectomy

Disease-specific death and metastasis do not occur in patients with Gleason score 6 at radical prostatectomy Disease-specific death and metastasis do not occur in patients with at radical prostatectomy Charlotte F. Kweldam, Mark F. Wildhagen*, Chris H. Bangma* and Geert J.L.H. van Leenders Departments of Pathology,

More information

Prognostic value of the Gleason score in prostate cancer

Prognostic value of the Gleason score in prostate cancer BJU International (22), 89, 538 542 Prognostic value of the Gleason score in prostate cancer L. EGEVAD, T. GRANFORS*, L. KARLBERG*, A. BERGH and P. STATTIN Department of Pathology and Cytology, Karolinska

More information

PSA is rising: What to do? After curative intended radiotherapy: More local options?

PSA is rising: What to do? After curative intended radiotherapy: More local options? Klinik und Poliklinik für Urologie und Kinderurologie Direktor: Prof. Dr. H. Riedmiller PSA is rising: What to do? After curative intended radiotherapy: More local options? Klinische und molekulare Charakterisierung

More information

Prostate cancer ~ diagnosis and impact of pathology on prognosis ESMO 2017

Prostate cancer ~ diagnosis and impact of pathology on prognosis ESMO 2017 Prostate cancer ~ diagnosis and impact of pathology on prognosis ESMO 2017 Dr Puay Hoon Tan Division of Pathology Singapore General Hospital Prostate cancer (acinar adenocarcinoma) Invasive carcinoma composed

More information

Prostate Cancer Local or distant recurrence?

Prostate Cancer Local or distant recurrence? Prostate Cancer Local or distant recurrence? Diagnostic flowchart Vanessa Vilas Boas Urologist VFX Hospital FEBU PSA - only recurrence PSA recurrence: 27-53% of all patients undergoing treatment with curative

More information

Introduction. Key Words: high-grade prostatic intraepithelial neoplasia, HGPIN, radical prostatectomy, prostate biopsy, insignificant prostate cancer

Introduction. Key Words: high-grade prostatic intraepithelial neoplasia, HGPIN, radical prostatectomy, prostate biopsy, insignificant prostate cancer Prostate cancer after initial high-grade prostatic intraepithelial neoplasia and benign prostate biopsy Premal Patel, MD, 1 Jasmir G. Nayak, MD, 1,2 Zlatica Biljetina, MD, 4 Bryan Donnelly, MD 3, Kiril

More information

Radical prostatectomy as radical cure of prostate cancer in a high risk group: A single-institution experience

Radical prostatectomy as radical cure of prostate cancer in a high risk group: A single-institution experience MOLECULAR AND CLINICAL ONCOLOGY 1: 337-342, 2013 Radical prostatectomy as radical cure of prostate cancer in a high risk group: A single-institution experience NOBUKI FURUBAYASHI 1, MOTONOBU NAKAMURA 1,

More information

How to deal with patients who fail intracavitary treatment

How to deal with patients who fail intracavitary treatment How to deal with patients who fail intracavitary treatment A. Heidenreich Department of Urology Non-surgical therapy of PCA IMRT SEEDS IGRT HDR-BRACHY HIFU CRYO LDR - Brachytherapy Author Follow-up bned

More information

Outcomes of salvage radical prostatectomy following more than one failed local therapy

Outcomes of salvage radical prostatectomy following more than one failed local therapy Original Article - Urological Oncology https://doi.org/10.4111/icu.2018.59.3.152 pissn 2466-0493 eissn 2466-054X Outcomes of salvage radical prostatectomy following more than one failed local therapy Arjun

More information

Percent Gleason pattern 4 in stratifying the prognosis of patients with intermediate-risk prostate cancer

Percent Gleason pattern 4 in stratifying the prognosis of patients with intermediate-risk prostate cancer Review Article Percent Gleason pattern 4 in stratifying the prognosis of patients with intermediate-risk prostate cancer Meenal Sharma 1, Hiroshi Miyamoto 1,2,3 1 Department of Pathology and Laboratory

More information

GUIDELINEs ON PROSTATE CANCER

GUIDELINEs ON PROSTATE CANCER GUIDELINEs ON PROSTATE CANCER (Text update March 2005: an update is foreseen for publication in 2010. Readers are kindly advised to consult the 2009 full text print of the PCa guidelines for the most recent

More information

Short ( 1 mm) positive surgical margin and risk of biochemical recurrence after radical prostatectomy

Short ( 1 mm) positive surgical margin and risk of biochemical recurrence after radical prostatectomy Short ( 1 mm) positive surgical margin and risk of biochemical recurrence after radical prostatectomy Sergey Shikanov, Pablo Marchetti, Vikas Desai, Aria Razmaria, Tatjana Antic, Hikmat Al-Ahmadie*, Gregory

More information

Understanding the risk of recurrence after primary treatment for prostate cancer. Aditya Bagrodia, MD

Understanding the risk of recurrence after primary treatment for prostate cancer. Aditya Bagrodia, MD Understanding the risk of recurrence after primary treatment for prostate cancer Aditya Bagrodia, MD Aditya.bagrodia@utsouthwestern.edu 423-967-5848 Outline and objectives Prostate cancer demographics

More information

BIOCHEMICAL RECURRENCE POST RADICAL PROSTATECTOMY

BIOCHEMICAL RECURRENCE POST RADICAL PROSTATECTOMY BIOCHEMICAL RECURRENCE POST RADICAL PROSTATECTOMY AZHAN BIN YUSOFF AZHAN BIN YUSOFF 2013 SCENARIO A 66 year old man underwent Robotic Radical Prostatectomy for a T1c Gleason 4+4, PSA 15 ng/ml prostate

More information

Prostate Case Scenario 1

Prostate Case Scenario 1 Prostate Case Scenario 1 H&P 5/12/16: A 57-year-old Hispanic male presents with frequency of micturition, urinary urgency, and hesitancy associated with a weak stream. Over the past several weeks, he has

More information

Clinical Study Oncologic Outcomes of Surgery in T3 Prostate Cancer: Experience of a Single Tertiary Center

Clinical Study Oncologic Outcomes of Surgery in T3 Prostate Cancer: Experience of a Single Tertiary Center Advances in Urology Volume 22, Article ID 64263, 8 pages doi:.55/22/64263 Clinical Study Oncologic Outcomes of Surgery in T3 Prostate Cancer: Experience of a Single Tertiary Center D. Milonas, G. Smailyte,

More information

Introduction. Original Article

Introduction. Original Article bs_bs_banner International Journal of Urology (2015) 22, 363 367 doi: 10.1111/iju.12704 Original Article Prostate-specific antigen level, stage or Gleason score: Which is best for predicting outcomes after

More information

Evaluation of prognostic factors after radical prostatectomy in pt3b prostate cancer patients in Japanese population

Evaluation of prognostic factors after radical prostatectomy in pt3b prostate cancer patients in Japanese population Japanese Journal of Clinical Oncology, 2015, 45(8) 780 784 doi: 10.1093/jjco/hyv077 Advance Access Publication Date: 15 May 2015 Original Article Original Article Evaluation of prognostic factors after

More information

Prostate Cancer: 2010 Guidelines Update

Prostate Cancer: 2010 Guidelines Update Prostate Cancer: 2010 Guidelines Update James L. Mohler, MD Chair, NCCN Prostate Cancer Panel Associate Director for Translational Research, Professor and Chair, Department of Urology, Roswell Park Cancer

More information

Providing Treatment Information for Prostate Cancer Patients

Providing Treatment Information for Prostate Cancer Patients Providing Treatment Information for Prostate Cancer Patients For all patients with localized disease on biopsy For all patients with adverse pathology after prostatectomy See what better looks like Contact

More information

Update on Reporting Prostate Cancer Pathology

Update on Reporting Prostate Cancer Pathology Update on Reporting Prostate Cancer Pathology Dr. Andrew J. Evans MD, PhD, FACP, FRCPC Consultant in Genitourinary Pathology University Health Network, Toronto, ON None Disclosures Learning Objectives

More information

GUIDELINES ON PROSTATE CANCER

GUIDELINES ON PROSTATE CANCER 10 G. Aus (chairman), C. Abbou, M. Bolla, A. Heidenreich, H-P. Schmid, H. van Poppel, J. Wolff, F. Zattoni Eur Urol 2001;40:97-101 Introduction Cancer of the prostate is now recognized as one of the principal

More information

Accepted for publication 3 January 2005

Accepted for publication 3 January 2005 Original Article RACIAL DIFFERENCES IN PSA DOUBLING TIME AND RECURRENCE TEWARI et al. In a multi-institutional study authors from the USA and Austria attempt to determine if there are differences in several

More information

Presentation with lymphadenopathy

Presentation with lymphadenopathy Presentation with lymphadenopathy Theo M. de Reijke MD PhD FEBU Department of Urology Academic Medical Center Amsterdam Rationale for RRP in N+ disease Prevention local problems Better survival in limited

More information

Presentation with lymphadenopathy

Presentation with lymphadenopathy Presentation with lymphadenopathy Theo M. de Reijke MD PhD FEBU Department of Urology Academic Medical Center Amsterdam Rationale for RRP in N+ disease Prevention local problems Better survival in limited

More information

PET imaging of cancer metabolism is commonly performed with F18

PET imaging of cancer metabolism is commonly performed with F18 PCRI Insights, August 2012, Vol. 15: No. 3 Carbon-11-Acetate PET/CT Imaging in Prostate Cancer Fabio Almeida, M.D. Medical Director, Arizona Molecular Imaging Center - Phoenix PET imaging of cancer metabolism

More information

S1.04 Principal clinician. G1.01 Comments. G2.01 *Specimen dimensions (prostate) S2.02 *Seminal vesicles

S1.04 Principal clinician. G1.01 Comments. G2.01 *Specimen dimensions (prostate) S2.02 *Seminal vesicles Prostate Cancer Histopathology Reporting Proforma (Radical Prostatectomy) Includes the International Collaboration on Cancer reporting dataset denoted by * Family name Given name(s) Date of birth Sex Male

More information

A schematic of the rectal probe in contact with the prostate is show in this diagram.

A schematic of the rectal probe in contact with the prostate is show in this diagram. Hello. My name is William Osai. I am a nurse practitioner in the GU Medical Oncology Department at The University of Texas MD Anderson Cancer Center in Houston. Today s presentation is Part 2 of the Overview

More information

Chapter 6. Long-Term Outcomes of Radical Prostatectomy for Clinically Localized Prostate Adenocarcinoma. Abstract

Chapter 6. Long-Term Outcomes of Radical Prostatectomy for Clinically Localized Prostate Adenocarcinoma. Abstract Chapter 6 Long-Term Outcomes of Radical Prostatectomy for Clinically Localized Prostate Adenocarcinoma Vijaya Raj Bhatt 1, Carl M Post 2, Sumit Dahal 3, Fausto R Loberiza 4 and Jue Wang 4 * 1 Department

More information

in 32%, T2c in 16% and T3 in 2% of patients.

in 32%, T2c in 16% and T3 in 2% of patients. BJUI Gleason 7 prostate cancer treated with lowdose-rate brachytherapy: lack of impact of primary Gleason pattern on biochemical failure Richard G. Stock, Joshua Berkowitz, Seth R. Blacksburg and Nelson

More information

External validation of the Briganti nomogram to estimate the probability of specimen-confined disease in patients with high-risk prostate cancer

External validation of the Briganti nomogram to estimate the probability of specimen-confined disease in patients with high-risk prostate cancer External validation of the Briganti nomogram to estimate the probability of specimen-confined disease in patients with high-risk prostate cancer Mathieu Roumiguié, Jean-Baptiste Beauval, Thomas Filleron*,

More information

Correspondence should be addressed to Taha Numan Yıkılmaz;

Correspondence should be addressed to Taha Numan Yıkılmaz; Advances in Medicine Volume 2016, Article ID 8639041, 5 pages http://dx.doi.org/10.1155/2016/8639041 Research Article External Validation of the Cancer of the Prostate Risk Assessment Postsurgical Score

More information

I have no financial relationships to disclose. I WILL NOT include discussion of investigational or off-label use of a product in my presentation.

I have no financial relationships to disclose. I WILL NOT include discussion of investigational or off-label use of a product in my presentation. Prostate t Cancer MR Report Disclosure Information Vikas Kundra, M.D, Ph.D. I have no financial relationships to disclose. I WILL NOT include discussion of investigational or off-label use of a g product

More information

Radical prostatectomy is the most widely used treatment. Partial Sampling of Radical Prostatectomy Specimens

Radical prostatectomy is the most widely used treatment. Partial Sampling of Radical Prostatectomy Specimens ORIGINAL ARTICLE Detection of Positive Margins and Extraprostatic Extension Viacheslav Iremashvili, MD, PhD,* Soum D. Lokeshwar,* Mark S. Soloway, MD,* Lise tpelaez,md,w Saleem A. Umar, MD,w Murugesan

More information

Best Papers. F. Fusco

Best Papers. F. Fusco Best Papers UROLOGY F. Fusco Best papers - 2015 RP/RT Oncological outcomes RP/RT IN ct3 Utilization trends RP/RT Complications Evolving role of elnd /Salvage LND This cohort reflects the current clinical

More information

2015 myresearch Science Internship Program: Applied Medicine. Civic Education Office of Government and Community Relations

2015 myresearch Science Internship Program: Applied Medicine. Civic Education Office of Government and Community Relations 2015 myresearch Science Internship Program: Applied Medicine Civic Education Office of Government and Community Relations Harguneet Singh Science Internship Program: Applied Medicine Comparisons of Outcomes

More information

Salvage Radical Prostatectomy for Radiation-recurrent Prostate Cancer: A Multi-institutional Collaboration

Salvage Radical Prostatectomy for Radiation-recurrent Prostate Cancer: A Multi-institutional Collaboration EUROPEAN UROLOGY 60 (2011) 205 210 available at www.sciencedirect.com journal homepage: www.europeanurology.com Platinum Priority Prostate Cancer Editorial by Markus Graefen on pp. 211 213 of this issue

More information

In 2005, International Society of Urological Pathology

In 2005, International Society of Urological Pathology ORIGINAL ARTICLE Gleason Score 3+4=7 Prostate Cancer With Minimal Quantity of Gleason Pattern 4 on Needle Biopsy Is Associated With Low-risk Tumor in Radical Prostatectomy Specimen Cheng Cheng Huang, MD,*

More information

Department of Urology, Cochin hospital Paris Descartes University

Department of Urology, Cochin hospital Paris Descartes University Technical advances in the treatment of localized prostate cancer Pr Michaël Peyromaure Department of Urology, Cochin hospital Paris Descartes University Introduction Curative treatments of localized prostate

More information

S1.04 PRINCIPAL CLINICIAN G1.01 COMMENTS S2.01 SPECIMEN LABELLED AS G2.01 *SPECIMEN DIMENSIONS (PROSTATE) S2.03 *SEMINAL VESICLES

S1.04 PRINCIPAL CLINICIAN G1.01 COMMENTS S2.01 SPECIMEN LABELLED AS G2.01 *SPECIMEN DIMENSIONS (PROSTATE) S2.03 *SEMINAL VESICLES Prostate Cancer Histopathology Reporting Proforma (Radical Prostatectomy) Includes the International Collaboration on Cancer reporting dataset denoted by * Family name Given name(s) Date of birth Indigenous

More information

Evaluation of the 7th American Joint Committee on Cancer TNM Staging System for Prostate Cancer in Point of Classification of Bladder Neck Invasion

Evaluation of the 7th American Joint Committee on Cancer TNM Staging System for Prostate Cancer in Point of Classification of Bladder Neck Invasion Jpn J Clin Oncol 2013;43(2)184 188 doi:10.1093/jjco/hys196 Advance Access Publication 5 December 2012 Evaluation of the 7th American Joint Committee on Cancer TNM Staging System for Prostate Cancer in

More information

INTRADUCTAL LESIONS OF THE PROSTATE. Jonathan I. Epstein

INTRADUCTAL LESIONS OF THE PROSTATE. Jonathan I. Epstein INTRADUCTAL LESIONS OF THE PROSTATE Jonathan I. Epstein Topics Prostatic intraepithelial neoplasia (PIN) Intraductal adenocarcinoma (IDC-P) Intraductal urothelial carcinoma Ductal adenocarcinoma High Prostatic

More information

Oncologic Outcome of Robot-Assisted Laparoscopic Prostatectomy in the High-Risk Setting

Oncologic Outcome of Robot-Assisted Laparoscopic Prostatectomy in the High-Risk Setting END-2010-0305-ver9-Engel_1P.3d 09/17/10 2:42pm Page 1 END-2010-0305-ver9-Engel_1P Type: research-article JOURNAL OF ENDOUROLOGY Volume 24, Number 00, XXXX 2010 ª Mary Ann Liebert, Inc. Pp. &&& &&& DOI:

More information

Prostate MRI: Who needs it?

Prostate MRI: Who needs it? Prostate MRI: Who needs it? Fergus Coakley MD, Professor of Radiology and Urology, Vice Chair for Clinical Services, Chief of Abdominal Imaging, UCSF Abdominal Imaging Magnetic Resonance Science Center

More information

Prognostic Value of Surgical Margin Status for Biochemical Recurrence Following Radical Prostatectomy

Prognostic Value of Surgical Margin Status for Biochemical Recurrence Following Radical Prostatectomy Original Article Japanese Journal of Clinical Oncology Advance Access published January 17, 2008 Jpn J Clin Oncol doi:10.1093/jjco/hym135 Prognostic Value of Surgical Margin Status for Biochemical Recurrence

More information

Since the beginning of the prostate-specific antigen (PSA) era in the. Characteristics of Insignificant Clinical T1c Prostate Tumors

Since the beginning of the prostate-specific antigen (PSA) era in the. Characteristics of Insignificant Clinical T1c Prostate Tumors 2001 Characteristics of Insignificant Clinical T1c Prostate Tumors A Contemporary Analysis Patrick J. Bastian, M.D. 1 Leslie A. Mangold, B.A., M.S. 1 Jonathan I. Epstein, M.D. 2 Alan W. Partin, M.D., Ph.D.

More information

Low risk. Objectives. Case-based question 1. Evidence-based utilization of imaging in prostate cancer

Low risk. Objectives. Case-based question 1. Evidence-based utilization of imaging in prostate cancer Evidence-based utilization of imaging in prostate cancer Fergus Coakley MD, Professor of Radiology and Urology, Vice Chair for Clinical Services, Chief of Abdominal Imaging, UCSF Objectives State the modalities,

More information

Prostatectomy as salvage therapy. Cases. Paul Cathcart - Guy s & St Thomas NHS Trust, London

Prostatectomy as salvage therapy. Cases. Paul Cathcart - Guy s & St Thomas NHS Trust, London Prostatectomy as salvage therapy Cases Paul Cathcart - Guy s & St Thomas NHS Trust, London Attributes of brachytherapy appeal to young men who place high utility on genitourinary function At risk of

More information

Case Scenario 1. 4/19/13 Bone Scan: No scintigraphic findings to suggest skeletal metastases.

Case Scenario 1. 4/19/13 Bone Scan: No scintigraphic findings to suggest skeletal metastases. Case Scenario 1 3/8/13 H&P 68 YR W/M presents w/elevated PSA. Patient is a non-smoker, current alcohol use. Physical Exam: On digital rectal exam the sphincter tone is normal and there is a 1 cm nodule

More information

Pathologists Perspective on Focal Therapy: The Role of Mapping Biopsies and Markers

Pathologists Perspective on Focal Therapy: The Role of Mapping Biopsies and Markers Pathologists Perspective on Focal Therapy: The Role of Mapping Biopsies and Markers M. Scott Lucia, MD Professor and Vice Chair of Anatomic Pathology Chief of Genitourinary and Renal Pathology Dept. of

More information

AJCC Cancer Staging 8 th Edition. Prostate Chapter 58. Executive Committee, AJCC. Professor and Director, Duke Prostate Center

AJCC Cancer Staging 8 th Edition. Prostate Chapter 58. Executive Committee, AJCC. Professor and Director, Duke Prostate Center AJCC Cancer Staging 8 th Edition Prostate Chapter 58 Judd W Moul, MD, FACS Executive Committee, AJCC Professor and Director, Duke Prostate Center Duke University Durham, North Carolina Validating science.

More information

Salvage HDR Brachytherapy. Amit Bahl Consultant Clinical Oncologist The Bristol Cancer Institute, UK

Salvage HDR Brachytherapy. Amit Bahl Consultant Clinical Oncologist The Bristol Cancer Institute, UK Salvage HDR Brachytherapy Amit Bahl Consultant Clinical Oncologist The Bristol Cancer Institute, UK Disclosures Still No financial disclosures! Limited personal experience of HDR Brachy as salvage option

More information

Procedures Needle Biopsy Transurethral Prostatic Resection Suprapubic or Retropubic Enucleation (Subtotal Prostatectomy) Radical Prostatectomy

Procedures Needle Biopsy Transurethral Prostatic Resection Suprapubic or Retropubic Enucleation (Subtotal Prostatectomy) Radical Prostatectomy Prostate Gland Protocol applies to invasive carcinomas of the prostate gland. Protocol web posting date: July 2006 Protocol effective date: April 2007 Based on AJCC/UICC TNM, 6 th edition Procedures Needle

More information

Post Radical Prostatectomy Adjuvant Radiation in Patients with Seminal Vesicle Invasion - A Historical Series

Post Radical Prostatectomy Adjuvant Radiation in Patients with Seminal Vesicle Invasion - A Historical Series Post Radical Prostatectomy Adjuvant Radiation in Patients with Seminal Vesicle Invasion - A Historical Series E. Z. Neulander 1, K. Rubinov 2, W. Mermershtain 2, Z. Wajsman 3 1 Department of Urology, Soroka

More information

S Crouzet, O Rouvière, JY Chapelon, F Mege, X martin, A Gelet

S Crouzet, O Rouvière, JY Chapelon, F Mege, X martin, A Gelet S Crouzet, O Rouvière, JY Chapelon, F Mege, X martin, A Gelet Why HIFU? Efficacy demonstrated Real time control of the target Early control of the necrosis area is possible with MRI or TRUS using contrast

More information

New research in prostate brachytherapy

New research in prostate brachytherapy New research in prostate brachytherapy Dr Ann Henry Associate Professor in Clinical Oncology University of Leeds and Leeds Cancer Centre PIVOTAL boost opening 2017 To evaluate - The benefits of pelvic

More information

Diagnosis, pathology and prognosis including variant pathology

Diagnosis, pathology and prognosis including variant pathology PROSTATE CANCER Diagnosis, pathology and prognosis including variant pathology No Conflict of Interest Universitat Autónoma de Barcelona F.Algaba Section of Pathology PROSTATE CANCER Diagnosis, pathology

More information

Managing Prostate Cancer After Initital Treatment Fails: Are There Good Next Steps?

Managing Prostate Cancer After Initital Treatment Fails: Are There Good Next Steps? Managing Prostate Cancer After Initital Treatment Fails: Are There Good Next Steps? Michael J Zelefsky, M.D. Professor of Radiation Oncology Chief Brachytherapy Service Department of Radiation Oncology

More information

Radiation Therapy After Radical Prostatectomy

Radiation Therapy After Radical Prostatectomy Articles ISSN 1537-744X; DOI 10.1100/tsw.2004.93 Radiation Therapy After Radical Ali M. Ziada, M.D. and E. David Crawford, M.D. Division of Urology, University of Colorado, Denver, Colorado E-mails: aziada@mednet3.camed.eun.eg

More information

PROVIDING TREATMENT INFORMATION FOR PROSTATE CANCER PATIENTS

PROVIDING TREATMENT INFORMATION FOR PROSTATE CANCER PATIENTS PROVIDING TREATMENT INFORMATION FOR PROSTATE CANCER PATIENTS For patients with localized disease on biopsy* For patients with adverse pathology after prostatectomy Contact the GenomeDx Customer Support

More information

Research Article Long-Term Oncological Outcomes for Young Men Undergoing Radical Prostatectomy for Localized Prostate Cancer

Research Article Long-Term Oncological Outcomes for Young Men Undergoing Radical Prostatectomy for Localized Prostate Cancer Hindawi BioMed Research International Volume 2017, Article ID 9858923, 6 pages https://doi.org/10.1155/2017/9858923 Research Article Long-Term Oncological Outcomes for Young Men Undergoing Radical Prostatectomy

More information

Prostate cancer staging and datasets: The Nitty-Gritty. What determines our pathological reports? 06/07/2018. Dan Berney Maastricht 2018

Prostate cancer staging and datasets: The Nitty-Gritty. What determines our pathological reports? 06/07/2018. Dan Berney Maastricht 2018 Prostate cancer staging and datasets: The Nitty-Gritty What determines our pathological reports? Dan Berney Maastricht 2018 Biopsy reporting. How not to do it. The TNM 8 th edition. Changes good and bad

More information

Predictors of time to biochemical recurrence in a radical prostatectomy cohort within the PSA-era

Predictors of time to biochemical recurrence in a radical prostatectomy cohort within the PSA-era ORIGINAL RESEARCH Predictors of time to biochemical recurrence in a radical prostatectomy cohort within the PSA-era Ahva Shahabi, MPH, PhD; 1* Raj Satkunasivam, MD; 2* Inderbir S. Gill, MD; 2 Gary Lieskovsky,

More information

PSA nadir post LDR Brachytherapy and early Salvage Therapy. Dr Duncan McLaren UK & Ireland Users Group Meeting 2016

PSA nadir post LDR Brachytherapy and early Salvage Therapy. Dr Duncan McLaren UK & Ireland Users Group Meeting 2016 PSA nadir post LDR Brachytherapy and early Salvage Therapy Dr Duncan McLaren UK & Ireland Users Group Meeting 2016 Differences in PSA relapse rates based on definition used PSA ng/ml Recurrence ASTRO Recurrence

More information

Gleason Scoring System 2017 JASREMAN DHILLON, MD ASSOCIATE PROFESSOR, DEPARTMENT OF ANATOMIC PATHOLOGY, MOFFITT CANCER CENTER, TAMPA, FLORIDA

Gleason Scoring System 2017 JASREMAN DHILLON, MD ASSOCIATE PROFESSOR, DEPARTMENT OF ANATOMIC PATHOLOGY, MOFFITT CANCER CENTER, TAMPA, FLORIDA Gleason Scoring System 2017 JASREMAN DHILLON, MD ASSOCIATE PROFESSOR, DEPARTMENT OF ANATOMIC PATHOLOGY, MOFFITT CANCER CENTER, TAMPA, FLORIDA Learners Objectives u Latest changes per ISUP 2014 that impact

More information

3/23/2017. Significant Changes in Prostate Cancer Classification, Grading, Staging and Reporting. Disclosure of Relevant Financial Relationships

3/23/2017. Significant Changes in Prostate Cancer Classification, Grading, Staging and Reporting. Disclosure of Relevant Financial Relationships Disclosure of Relevant Financial Relationships Staging and Reporting of Prostate Cancer: Major Changes in 8 th Edition AJCC Staging and CAP Cancer Checklists USCAP requires that all planners (Education

More information

Predictive factors of late biochemical recurrence after radical prostatectomy

Predictive factors of late biochemical recurrence after radical prostatectomy JJCO Japanese Journal of Clinical Oncology Japanese Journal of Clinical Oncology, 2017, 47(3) 233 238 doi: 10.1093/jjco/hyw181 Advance Access Publication Date: 9 December 2016 Original Article Original

More information

Paul F. Schellhammer, M.D. Eastern Virginia Medical School Urology of Virginia Norfolk, Virginia

Paul F. Schellhammer, M.D. Eastern Virginia Medical School Urology of Virginia Norfolk, Virginia Paul F. Schellhammer, M.D. Eastern Virginia Medical School Urology of Virginia Norfolk, Virginia Virginia - Chesapeake Bay Landfall: Virginia Beach, April 29 th, 1607 PSA Failure after Radical Prostatectomy

More information

Radiation dose has been reported to be an important determinant

Radiation dose has been reported to be an important determinant 538 The Relationship of Increasing Radiotherapy Dose to Reduced Distant Metastases and Mortality in Men with Prostate Cancer Rojymon Jacob, M.D. 1 Alexandra L. Hanlon, Ph.D. 2 Eric M. Horwitz, M.D. 1 Benjamin

More information

Percentage of Gleason Pattern 4 and 5 Predicts Survival After Radical Prostatectomy

Percentage of Gleason Pattern 4 and 5 Predicts Survival After Radical Prostatectomy 1967 Percentage of Gleason Pattern 4 and 5 Predicts Survival After Radical Prostatectomy Liang Cheng, MD 1,2 Darrell D. Davidson, MD, PhD 1 Haiqun Lin, MD, PhD 3 Michael O. Koch, MD 2 1 Department of Pathology

More information

concordance indices were calculated for the entire model and subsequently for each risk group.

concordance indices were calculated for the entire model and subsequently for each risk group. ; 2010 Urological Oncology ACCURACY OF KATTAN NOMOGRAM KORETS ET AL. BJUI Accuracy of the Kattan nomogram across prostate cancer risk-groups Ruslan Korets, Piruz Motamedinia, Olga Yeshchina, Manisha Desai

More information

Prostate Cancer Grading, Staging and Reporting: An Update Cristina Magi-Galluzzi, MD, PhD

Prostate Cancer Grading, Staging and Reporting: An Update Cristina Magi-Galluzzi, MD, PhD Prostate Cancer Grading, Staging and Reporting: An Update Cristina Magi-Galluzzi, MD, PhD Director, Genitourinary Pathology R.J. Tomsich Pathology & Laboratory Medicine Institute Professor of Pathology,

More information

Use of the cell cycle progression (CCP) score for predicting systemic disease and response to radiation of biochemical recurrence

Use of the cell cycle progression (CCP) score for predicting systemic disease and response to radiation of biochemical recurrence Cancer Biomarkers 17 (2016) 83 88 83 DOI 10.3233/CBM-160620 IOS Press Use of the cell cycle progression (CCP) score for predicting systemic disease and response to radiation of biochemical recurrence Michael

More information

Lewis Garvey Smith III, MD Reference List

Lewis Garvey Smith III, MD Reference List Journal D'Souza WD, Lee HK, Palmer MB, Smith LG, Pollack A. Is intraoperative nomogram-based overplanning of prostate implants necessary? Int J Radiat.Oncol.Biol.Phys. 56[2], 462-467. 2003 Rosser CJ, Chichakli

More information

Supplemental Information

Supplemental Information Supplemental Information Prediction of Prostate Cancer Recurrence using Quantitative Phase Imaging Shamira Sridharan 1, Virgilia Macias 2, Krishnarao Tangella 3, André Kajdacsy-Balla 2 and Gabriel Popescu

More information

Utility of Prostate MRI. John R. Leyendecker, MD

Utility of Prostate MRI. John R. Leyendecker, MD Utility of Prostate MRI John R. Leyendecker, MD Professor of Radiology and Urology Executive Vice Chair of Clinical Operations Section Head, Abdominal Imaging Wake Forest University School of Medicine;

More information

Aram Kim 4, Myong Kim 1, Se Un Jeong 2, Cheryn Song 1, Yong Mee Cho 2, Jae Yoon Ro 3 and Hanjong Ahn 1*

Aram Kim 4, Myong Kim 1, Se Un Jeong 2, Cheryn Song 1, Yong Mee Cho 2, Jae Yoon Ro 3 and Hanjong Ahn 1* Kim et al. BMC Urology (2018) 18:7 DOI 10.1186/s12894-018-0321-z RESEARCH ARTICLE Open Access Level of invasion into fibromuscular band is an independent factor for positive surgical margin and biochemical

More information

Preoperative Gleason score, percent of positive prostate biopsies and PSA in predicting biochemical recurrence after radical prostatectomy

Preoperative Gleason score, percent of positive prostate biopsies and PSA in predicting biochemical recurrence after radical prostatectomy JBUON 2013; 18(4): 954-960 ISSN: 1107-0625, online ISSN: 2241-6293 www.jbuon.com E-mail: editorial_office@jbuon.com ORIGINAL ARTICLE Gleason score, percent of positive prostate and PSA in predicting biochemical

More information

Anatomic distribution and pathologic characterization of small-volume prostate cancer (o0.5 ml) in whole-mount prostatectomy specimens

Anatomic distribution and pathologic characterization of small-volume prostate cancer (o0.5 ml) in whole-mount prostatectomy specimens & 2005 USCAP, Inc All rights reserved 0893-3952/05 $30.00 www.modernpathology.org Anatomic distribution and pathologic characterization of small-volume prostate cancer (o0.5 ml) in whole-mount prostatectomy

More information

Prostate MRI for local staging and surgical planning in prostate cancer

Prostate MRI for local staging and surgical planning in prostate cancer Prostate MRI for local staging and surgical planning in prostate cancer 15th Annual Floyd A. Fried Advances in Urology Symposium June 23, 2017 Ray Tan, MD, MSHPM Assistant Professor Disclosures None Objectives

More information

Chapter 2. Understanding My Diagnosis

Chapter 2. Understanding My Diagnosis Chapter 2. Understanding My Diagnosis With contributions from Nancy L. Brown, Ph.D.,Palo Alto Medical Foundation Research Institute; and Patrick Swift, M.D., Alta Bates Comprehensive Cancer Program o Facts

More information

Radical Prostatectomy: Management of the Primary From Localized to Oligometasta:c Disease

Radical Prostatectomy: Management of the Primary From Localized to Oligometasta:c Disease Radical Prostatectomy: Management of the Primary From Localized to Oligometasta:c Disease Disclosures I do not have anything to disclose Sexual function causes moderate to severe distress 2 years after

More information

When PSA fails. Urology Grand Rounds Alexandra Perks. Rising PSA after Radical Prostatectomy

When PSA fails. Urology Grand Rounds Alexandra Perks. Rising PSA after Radical Prostatectomy When PSA fails Urology Grand Rounds Alexandra Perks Rising PSA after Radical Prostatectomy Issues Natural History Local vs Metastatic Treatment options 1 10 000 men / year in Canada 4000 RRP 15-year PSA

More information

Information Content of Five Nomograms for Outcomes in Prostate Cancer

Information Content of Five Nomograms for Outcomes in Prostate Cancer Anatomic Pathology / NOMOGRAMS IN PROSTATE CANCER Information Content of Five Nomograms for Outcomes in Prostate Cancer Tarek A. Bismar, MD, 1 Peter Humphrey, MD, 2 and Robin T. Vollmer, MD 3 Key Words:

More information

Case #1: 75 y/o Male (treated and followed by prostate cancer oncology specialist ).

Case #1: 75 y/o Male (treated and followed by prostate cancer oncology specialist ). SOLID TUMORS WORKSHOP Cases for review Prostate Cancer Case #1: 75 y/o Male (treated and followed by prostate cancer oncology specialist ). January 2009 PSA 4.4, 20% free; August 2009 PSA 5.2; Sept 2009

More information

Post Radical Prostatectomy Radiation in Intermediate and High Risk Group Prostate Cancer Patients - A Historical Series

Post Radical Prostatectomy Radiation in Intermediate and High Risk Group Prostate Cancer Patients - A Historical Series Post Radical Prostatectomy Radiation in Intermediate and High Risk Group Prostate Cancer Patients - A Historical Series E. Z. Neulander 1, Z. Wajsman 2 1 Department of Urology, Soroka UMC, Ben Gurion University,

More information

INCIDENTAL PROSTATE CANCER IN PATIENTS UNDERGOING RADICAL CYSTOPROSTATECTOMY FOR BLADDER CANCER

INCIDENTAL PROSTATE CANCER IN PATIENTS UNDERGOING RADICAL CYSTOPROSTATECTOMY FOR BLADDER CANCER & INCIDENTAL PROSTATE CANCER IN PATIENTS UNDERGOING RADICAL CYSTOPROSTATECTOMY FOR BLADDER CANCER Mustafa Hiroš *, Hajrudin Spahović, Mirsad Selimović, Sabina Sadović Urology Clinic, University of Sarajevo

More information

Focal Therapy is a Fool s Paradise : The whole prostate must be treated!

Focal Therapy is a Fool s Paradise : The whole prostate must be treated! Focal Therapy is a Fool s Paradise : The whole prostate must be treated! Ofer Yossepowitch, MD Head, Department of Urology Tel Aviv Sourasky Medical Center Preaching against focal therapy in a focal therapy

More information

When radical prostatectomy is not enough: The evolving role of postoperative

When radical prostatectomy is not enough: The evolving role of postoperative When radical prostatectomy is not enough: The evolving role of postoperative radiation therapy Dr Tom Pickles Clinical Associate Professor, UBC. Chair, Provincial Genito-Urinary Tumour Group BC Cancer

More information

Treatment Failure After Primary and Salvage Therapy for Prostate Cancer

Treatment Failure After Primary and Salvage Therapy for Prostate Cancer 307 Treatment Failure After Primary and Salvage Therapy for Prostate Cancer Likelihood, Patterns of Care, and Outcomes Piyush K. Agarwal, MD 1 Natalia Sadetsky, MD, MPH 2 Badrinath R. Konety, MD, MBA 2

More information

Risk Factors for Clinical Metastasis in Men Undergoing Radical Prostatectomy and Immediate Adjuvant Androgen Deprivation Therapy

Risk Factors for Clinical Metastasis in Men Undergoing Radical Prostatectomy and Immediate Adjuvant Androgen Deprivation Therapy RESEARCH ARTICLE Risk Factors for Clinical Metastasis in Men Undergoing Radical Prostatectomy and Immediate Adjuvant Androgen Deprivation Therapy Satoru Taguchi, Hiroshi Fukuhara*, Shigenori Kakutani,

More information

Hormone Therapy for Prostate Cancer: Guidelines versus Clinical Practice

Hormone Therapy for Prostate Cancer: Guidelines versus Clinical Practice european urology supplements 5 (2006) 362 368 available at www.sciencedirect.com journal homepage: www.europeanurology.com Hormone Therapy for Prostate Cancer: Guidelines versus Clinical Practice Antonio

More information

Newer Aspects of Prostate Cancer Underwriting

Newer Aspects of Prostate Cancer Underwriting Newer Aspects of Prostate Cancer Underwriting Presented By: Jack Swanson, M.D. Keith Hoffman, NFP Moments Made Possible Objectives To review and discuss Conflicting messages about PSA testing Cautions

More information

Radical prostate surgery?

Radical prostate surgery? Decipher enables personalized and actionable treatment after surgery Radical prostate surgery? The Decipher Prostate Cancer Classifier can help you and your doctor decide on important next steps in your

More information

Effective Date: 11/1/2018 Section: SUR Policy No: 420 Medical Policy Committee Approved Date: 8/18; 9/18

Effective Date: 11/1/2018 Section: SUR Policy No: 420 Medical Policy Committee Approved Date: 8/18; 9/18 PROVIDENCE HEALTH PLANS MEDICAL (HIFU) (All Lines of Business Except Medicare) Effective Date: 11/1/2018 Section: SUR Policy No: 420 Medical Policy Committee Approved Date: 8/18; 9/18 11/1/18 Medical Officer

More information

1. INTRODUCTION. ARC Journal of Urology Volume 1, Issue 1, 2016, PP 1-7 Abstract:

1. INTRODUCTION. ARC Journal of Urology Volume 1, Issue 1, 2016, PP 1-7  Abstract: ARC Journal of Urology Volume 1, Issue 1, 2016, PP 1-7 www.arcjournals.org Does the Number of Lymph Nodes Removed During Radical Prostatectomy Impact Risk of Biochemical Recurrence in Patients With Isolated

More information

Localized Prostate Cancer Have we finally got it right? Shingai Mutambirwa Professor & Chair-Division Urology DGMAH & SMU Pretoria SOUTH AFRICA

Localized Prostate Cancer Have we finally got it right? Shingai Mutambirwa Professor & Chair-Division Urology DGMAH & SMU Pretoria SOUTH AFRICA Localized Prostate Cancer Have we finally got it right? Shingai Mutambirwa Professor & Chair-Division Urology DGMAH & SMU Pretoria SOUTH AFRICA ESMO Cape Town 14 Feb 2018 Disclosures Advisory boards/lecturer/consultant-

More information